Objective:

The article examines uptake and timing of molecular testing among older Medicare beneficiaries with advanced NSCLC in rural US counties from 2014 through 2019, and discusses the implications for timely, equitable access to precision oncology.

Approach:

• Historical cohort: Rhinehart and colleagues assessed molecular testing in 8,259 older Medicare beneficiaries with advanced NSCLC in rural US counties from 2014 through 2019.
• Implementation context: The article relates those findings to current guidance, a prospective US community-practice cohort, and reports on diagnostic pathways and precision-oncology networks.

Key Findings:

• Molecular testing was performed in 35.9% of the rural cohort overall, increasing from 18% by 30 days to 30% by 60 days and 36% by 180 days after diagnosis.
• Testing was less frequent among older patients, patients with dual Medicare and Medicaid coverage, and patients with squamous histology.
• Among patients surviving at least 6 months, 77.7% of those tested had seen both an oncologist and a proceduralist or surgeon, compared with 58.9% of those not tested.
• In a separate 2020–2022 cohort of 556 patients with metastatic NSCLC, next-generation sequencing was performed in 72.8%; results preceded first-line treatment in 55.6%, and complete guideline-concordant biomarker results were available before therapy in 44.1%.
• The article reports that early plasma genotyping has been associated with faster molecular results and earlier treatment initiation, and describes network models that connect centers for centralized genomic profiling and specialist interpretation.

Interpretation:

The article frames molecular testing as one measure of precision-care access and emphasizes whether comprehensive results reach eligible patients before treatment decisions. It identifies coordinated pathways, specialist networks, and systems for ordering, tracking, and reporting as approaches discussed for improving access and timeliness.

Limitations:

• The Medicare claims analysis cannot fully capture clinical fitness, treatment eligibility, or patient preferences that may contribute to observed associations.
• The cohort reflects rural US counties and the 2014–2019 period; the article notes that barriers and health-system contexts differ across countries.

Conclusion:

The article presents the rural cohort as a historical benchmark and discusses the importance of coordinated care pathways that make comprehensive molecular results available when treatment decisions are made.

Sources:

• Article context supplied by the user